Harmony Biosciences Holdings 1 article

Harmony Biosciences Holdings is a biopharmaceutical company characterized by Biosciences sleep-wake therapeutics and histamine H3 receptor antagonism; its scientific profile also incorporates H3 receptor inverse agonism. At Harmony Biosciences Holdings, H3 receptor inverse agonism sits alongside narcolepsy therapeutics; histaminergic wakefulness signaling adds disease-specific context to the therapeutic profile. GenoMethods uses neuronal histamine modulation to help recognize Harmony Biosciences Holdings, without treating any one product or target as the company itself.

Biotech Companies & Pipelines

October 1, 2026, 9:45 AM · 3 mins read

HBM Healthcare Investments forecasts sharp profit jump as private biotech deals pay off

HBM Healthcare Investments expects a half-year profit of CHF 177 million, fueled by big gains in private biotech holdings and major exits, even as listed assets remain volatile.